(Q45362210)

13 December 2017

title

Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients (English)

1 reference

13 December 2017

1 reference

15

Namiki Izumi

1 reference

13 December 2017

Hiroko Shindo

1

1 reference

13 December 2017

Shinya Maekawa

2

1 reference

13 December 2017

Kazuki Komase

3

1 reference

13 December 2017

Ryota Sueki

4

1 reference

13 December 2017

Mika Miura

5

1 reference

13 December 2017

Makoto Kadokura

6

1 reference

13 December 2017

Kuniaki Shindo

7

1 reference

13 December 2017

Fumitake Amemiya

8

1 reference

13 December 2017

Takatoshi Kitamura

9

1 reference

13 December 2017

Yasuhiro Nakayama

10

1 reference

13 December 2017

Taisuke Inoue

11

1 reference

13 December 2017

Minoru Sakamoto

12

1 reference

13 December 2017

Shun-Ichi Okada

13

1 reference

13 December 2017

Yasuhiro Asahina

14

1 reference

13 December 2017

Masao Honda

16

1 reference

13 December 2017

Shuichi Kaneko

17

1 reference

13 December 2017

Nobuyuki Enomoto

18

1 reference

13 December 2017

publication date

18 August 2011

1 reference

13 December 2017

published in

Hepatology international

1 reference

13 December 2017

volume

6

1 reference

13 December 2017

issue

2

1 reference

13 December 2017

page(s)

482-490

1 reference

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Characterization of resistance mutations against HCV ketoamide protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Care of patients with hepatitis C and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9306-7

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.

21 January 2018

1 reference

12 December 2020

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease

1 reference

12 December 2020

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

1 reference

12 December 2020

Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates

1 reference

12 December 2020

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

12 December 2020

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

1 reference

12 December 2020

Telaprevir for previously treated chronic HCV infection

1 reference

12 December 2020

10.1007/S12072-011-9306-7

Identifiers

DOI

1 reference

Dimensions Publication ID

13 December 2017

1013927705

0 references

1 reference